FDA reversal reopens Huntington’s therapy approval path

Summary

The FDA has dropped its earlier objections and told UniQure it can proceed with submitting its experimental Huntington’s disease therapy for approval. The decision reopens a regulatory path for a high-profile program that had been stalled by agency concerns.

Why it matters

It changes the probability that a disease-modifying Huntington’s treatment could reach the market and signals how the FDA may handle disputed evidence in neurology gene-therapy programs.

Summary

UniQure says the FDA will let it pursue US approval for its Huntington’s disease gene therapy without first running a new clinical study. The decision reverses an earlier stance and triggered a sharp jump in UniQure’s shares.

Why it matters

FDA willingness to approve without new trials can accelerate treatments and investment, but it also resets the evidentiary bar for gene therapies with serious safety and durability questions.

Summary

Health officials warn the latest Ebola outbreak could become the worst on record because transmission is outpacing case finding and contact tracing. A sharp drop in international funding is limiting surveillance, staffing, and basic outbreak control.

Why it matters

When Ebola spreads faster than it can be traced, containment fails and a local outbreak can turn into a regional crisis.

Summary

The FTC and attorneys general from four states sued the leading professional association for clinicians who provide gender-affirming care. The case challenges the group’s role in setting clinical standards and influencing how providers and insurers deliver and cover this care.

Why it matters

It puts the legal status of medical guideline-making in the crosshairs and could reshape access, coverage, and liability around gender-affirming care nationwide.